ReviewCVIR endovascular2026
Uterine artery embolization for the treatment of symptomatic adenomyosis: a systematic review.
Review in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenomyosis is a benign uterine condition characterized by the presence of glands and endometrial stroma in the myometrium, with hypertrophy of the smooth muscle cells and uterine enlargement, and causing chronic pelvic pain, dysmenorrhea, and abnormal uterine bleeding, resulting in significant impairment of quality of life. In the last decades, the role of interventional radiology has expanded the range of treatment options of this condition, and uterine artery embolization (UAE) has emerged as a minimally invasive therapy in the management of symptomatic adenomyosis. This systematic review aims to evaluate the efficacy and safety of UAE in patients with symptomatic adenomyosis.
methodsA systematic literature search was conducted across PubMed, Embase, Cochrane Library, Google Scholar, and Medline database, including studies published up to December 2025. Eligible articles included prospective and retrospective observational cohort studies with more than ten patients reporting UAE outcomes for adenomyosis; case report, case series, narrative or systematic review, meta-analysis, and guidelines were considered as not eligible and were therefore excluded. The data analyzed included patient characteristics, technical and clinical success, symptom improvement, imaging outcomes, reintervention rate, and complications, the latter classified according to the new modified CIRSE classification grading system.
resultsTwenty-two studies met the inclusion criteria and we collected data on 1701 patients who underwent uterine embolization for therapy-resistant adenomyosis. UAE has demonstrated high technical success rates across studies with 1301/1701 (76.4%) patients experienced significant improvement in heavy menstrual bleeding, dysmenorrhea, and bulky-related symptoms at short- and mid-term follow-up. Imaging assessments showed reductions in uterine volume and junctional zone thickness; reintervention and hysterectomy rates were low. Reported complications were predominantly minor, with a low incidence of major adverse events. The mortality rate post-procedure was 0%.
conclusionsBased on available literature, UAE represents a safe and effective uterus-preserving minimally invasive treatment for selected patients with symptomatic adenomyosis; it represents a step on the treatment pathway before hysterectomy, and women should have access to consult with interventional radiologists when making any treatment decision, in order to achieve a personalized treatment plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.